United Therapeutics/$UTHR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About United Therapeutics
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Ticker
$UTHR
Sector
Primary listing
Employees
1,400
Headquarters
Website
UTHR Metrics
BasicAdvanced
$23B
19.24
$27.86
0.86
-
Price and volume
Market cap
$23B
Beta
0.86
52-week high
$548.12
52-week low
$266.98
Average daily volume
481K
Financial strength
Current ratio
6.605
Quick ratio
5.834
Long term debt to equity
0.427
Total debt to equity
0.53
Interest coverage (TTM)
77.70%
Profitability
EBITDA (TTM)
1,600.8
Gross margin (TTM)
87.92%
Net profit margin (TTM)
41.94%
Operating margin (TTM)
47.61%
Effective tax rate (TTM)
22.12%
Revenue per employee (TTM)
$2,270,000
Management effectiveness
Return on assets (TTM)
12.42%
Return on equity (TTM)
19.71%
Valuation
Price to earnings (TTM)
19.243
Price to revenue (TTM)
7.462
Price to book
3.3
Price to tangible book (TTM)
3.35
Price to free cash flow (TTM)
22.943
Free cash flow yield (TTM)
4.36%
Free cash flow per share (TTM)
23.368
Growth
Revenue change (TTM)
10.61%
Earnings per share change (TTM)
13.07%
3-year revenue growth (CAGR)
18.02%
10-year revenue growth (CAGR)
8.06%
3-year earnings per share growth (CAGR)
22.92%
10-year earnings per share growth (CAGR)
8.16%
What the Analysts think about UTHR
Analyst ratings (Buy, Hold, Sell) for United Therapeutics stock.
UTHR Financial Performance
Revenues and expenses
UTHR Earnings Performance
Company profitability
UTHR News
AllArticlesVideos
United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine
Business Wire·5 days ago
United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
Business Wire·2 weeks ago
United Therapeutics' blood pressure drug meets main, secondary goals in late-stage study
Reuters·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for United Therapeutics stock?
United Therapeutics (UTHR) has a market cap of $23B as of March 16, 2026.
What is the P/E ratio for United Therapeutics stock?
The price to earnings (P/E) ratio for United Therapeutics (UTHR) stock is 19.24 as of March 16, 2026.
Does United Therapeutics stock pay dividends?
No, United Therapeutics (UTHR) stock does not pay dividends to its shareholders as of March 16, 2026.
When is the next United Therapeutics dividend payment date?
United Therapeutics (UTHR) stock does not pay dividends to its shareholders.
What is the beta indicator for United Therapeutics?
United Therapeutics (UTHR) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.